Prospective study of 305 Consecutive newly diagnosed axSpA pts (55% male; Dx delay 6 yrs; 75% B27+). 56% w/ r-axSpA more male w/ hi CRP. nr-axSpA had more inflam LBP, +FHx SpA. SpA Dx made without sacroiliitis in 12%; only 2/38 later developed sacroiliitis https://t.co/xPlGwZ7Kjk https://t.co/2TBQALvxsG

Anifrolumab (Saphnelo) approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus based on SC-TULIP study. Presumeably, all prior CRL issues resolved to FDA satisfaction... https://t.co/ZtZmJLcGYa https://t.co/4B2YDpFaep

Which autoimmune condition carries the highest relative risk for lymphoma? Test your knowledge in the latest RheumIQ quiz at https://t.co/TBlB4pmnKa https://t.co/sx8fpdHgHN

Review of GLP-1 Receptor Agonists in Psoriasis Psoriasis is a chronic immune-mediated inflammatory disease plaqued by systemic comorbidities that increase morbidity, mortality, and treatment complexity. Obesity is a significant contributor to psoriatic disease. https://t.co/R1Uutdjcvz

FDA Targeting the Safety of Avacopan The future of avacopan is up in the air. In April, the FDA issued a drug safety warning, previously requesting that Amgen to pull its rare disease drug Tavneos from the market. Now, there appears more pressure to remove it from the market. https://t.co/4PyIoqwNIL

APR: Steroids https://t.co/FxqGaijo6w https://t.co/OrybGNXsdf

EULAR Recommendations for Physical Activity in Arthritis EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA). https://t.co/RFECflCUgf https://t.co/Da7D6KpN6q

Among 1074 #PsA tested annually, RF positivity was found in 16.1% overall (5.1% RF+ at baseline). RF+ rediced odds of MDA (OR 0.53) w/ incr risk of bDMARD discontinuation (OR 2.65) https://t.co/RS3BvufE7F https://t.co/cxKk2xZmoS

Synovial tissue study from 244 #OA pts undergoing surgery, finds variable synovial pathotypes - High-grade synovitis in 64% (55% lympho-myeloid, 12% diffuse-myeloid, 33% pauci-immune). Lympho-myeloid had highest inflammation, incr by high BMI. https://t.co/cc0Z3KWtY0 https://t.co/zf7r23KGCy

RA is significantly associated with an increased risk of osteoporotic fractures (OPF) -RR 1.47 (1.32–1.64), for both female (1.39) & male(1.69) pts. Metanalysis of OPF in RA (7 cohort studies, 12,408pts). https://t.co/XP719A3ZM6 https://t.co/40phL7K9EB

Neoplasia and Autoimmune Disease Malignancy rivals cardiovascular disease as a leading cause of death in patients with systemic autoimmune diseases. Chronic inflammation and immune dysregulation can drive oncogenesis, while antitumor immune responses can trigger autoimmune https://t.co/uIsVl1N1hH

Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA After the first tumor necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab. https://t.co/mEaUcBD2ZK